Historically, the strength of the European Union has been defined by its ability to harmonise social progress with economic stability. Today, this balance depends on our capacity to safeguard the cognitive health of our population.

To succeed, Europe needs to move beyond a ‘health budget’ mindset – which views healthcare as a fiscal cost – towards a model that treats the life sciences as a fundamental investment in our long-term prosperity. This transition requires a synchronised effort across the legislative landscape to ensure that scientific innovation translates into tangible outcomes.

Health policy should be viewed on a par with industrial policy; investing in the brain is an investment in the future of the European workforce and the sustainability of our social model.

A clear trend has emerged in the global life sciences landscape, characterised by a steady migration of research and investment towards North America and Asia. This is reflected in the 10% drop in Europe’s share of global clinical trials over the last decade. Consequently, the industry faces an ‘access paradox’ where European breakthroughs face significant delays in reaching the clinical trial setting due to regulatory fragmentation.

The direct result of this competitive decline is a widening access gap: approximately 60,000 fewer Europeans benefit from the latest experimental therapies through clinical trials annually compared to a decade ago. This loss of activity deprives patients of early access to life-saving interventions and slows the gathering of essential real-world evidence.

Addressing these gaps requires a modernised regulatory toolkit, beginning with the European Health Data Space (EHDS) implementation. The EHDS can transform the sector by enabling in silico trials, using computer modelling and virtual patient cohorts to make clinical validation both faster and more cost-effective. This digital transformation is key to unlocking personalised medicine for millions, allowing for increased precise recruitment and a more responsive approach to rare neurological conditions.

By creating a unified framework for health data, Europe can set a global standard for ethical, secure and efficient medical research.

Alongside data optimisation, the EU Biotech Act serves as a necessary enabler for high-risk research, ensuring that Europe remains a global destination for the development of life-changing therapies. Innovation thrives where there is legal certainty and robust protection for the decades of research required to tackle complex brain conditions. Together, these two initiatives create the pathway innovators need to move from discovery to delivery without the administrative friction that characterises the existing landscape.

These regulatory tools require a robust financial engine to achieve their full potential. A clear necessity exists for a ring-fenced brain research budget within the next Multiannual Financial Framework to provide the long-term stability healthcare projects require.

Brain research needs financial commitments that give researchers the confidence to pursue transformative, long-term R&D. Without this certainty, European talent will continue to seek opportunities outside our borders, leading to a ‘brain drain’ as detrimental as the migration of clinical trials.

This is why the 10th Framework Programme is pivotal, providing the sustained investment cycles needed to bridge the gap between early-stage research and clinical availability.

Moreover, this funding must be concentrated on large-scale strategic goals to ensure that medical innovations are successfully integrated into national healthcare systems rather than stalling in development.

Success should be measured in patient outcomes and the reduction of the socio-economic burden of brain-related disability.

Epilepsy, a condition affecting six million Europeans, serves as a primary case study for this policy-to-practice gap. Here, the divide between scientific potential and the reality of patient care is addressable through coordinated infrastructure rather than new discovery alone.

This disparity acts as a call for a unified European health response that ensures geography does not dictate the quality of treatment or the speed of access to specialised care. Furthermore, the high rate of comorbidities in epilepsy – such as depression and anxiety – proves that neurological and mental health cannot be treated in silos; it requires cross-disciplinary care pathways.

The Intersectoral Global Action Plan for epilepsy and other neurological disorders (IGAP) serves as the catalyst for this change by standardising diagnostic protocols and resource allocation across Member States.

By aligning national systems with shared clinical benchmarks, the plan ensures that best practices are adopted consistently regardless of borders. The ambition is to facilitate the 70% seizure-free success rate that is clinically possible but hindered by systemic inequalities.

In this way, epilepsy provides a scalable blueprint for addressing other complex neurological conditions, from Alzheimer’s to Parkinson’s, by proving that policy coordination directly improves clinical outcomes.

The upcoming legislative cycle represents a critical opportunity to align the budget, research and regulation needed to create a seamless continuum from innovation to care. While scientific leadership is the first step, its value is only fully realised when paired with the political infrastructure to deliver outcomes to the 179 million citizens in Europe living with brain conditions. By aligning our industrial goals with our public health needs, we ensure the ‘European brain’ remains at the forefront of global progress.

The window to align these efforts is opening now. The future of European healthcare and prosperity depends on the strategic decisions we make today. We have the science and the vision; now is the time for the political will to connect them.

References available on request